Literature DB >> 23303805

A recently isolated Lassa virus from Mali demonstrates atypical clinical disease manifestations and decreased virulence in cynomolgus macaques.

David Safronetz1, James E Strong, Friederike Feldmann, Elaine Haddock, Nafomon Sogoba, Douglas Brining, Thomas W Geisbert, Dana P Scott, Heinz Feldmann.   

Abstract

The virulence of Soromba-R, a Lassa virus strain recently isolated from southern Mali, was assessed in 2 animal models of Lassa fever: inbred strain 13 guinea pigs and cynomolgus macaques. In both models, the Malian isolate demonstrated tissue tropism and viral titers similar to those of historical Lassa virus isolates from Sierra Leone (Josiah) and Liberia (Z-132); however, the Soromba-R isolate was found to be less pathogenic, as determined by decreased mortality and prolonged time to euthanasia in macaques. Interestingly, in addition to the classic indicators of Lassa fever, Soromba-R infection presented with moderate to severe pulmonary manifestations in the macaque model. Analysis of host responses demonstrated increased immune activation in Soromba-R-infected macaques, particularly in neutrophil-activating or -potentiating proinflammatory cytokines or growth factors, including tumor necrosis factor α, macrophage inflammatory protein 1α, interleukin 1β, and granulocyte colony-stimulating factor, as well as interleukin 5, which may be responsible for the decreased lethality and uncharacteristic clinical presentation. These results suggest that the strain of Lassa virus circulating in Mali might be less pathogenic than strains circulating in the historical region of endemicity and may result in an atypical presentation for Lassa fever, which could complicate clinical diagnosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23303805      PMCID: PMC3603532          DOI: 10.1093/infdis/jit004

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  41 in total

1.  The first case of Lassa fever imported from Mali to the United Kingdom, February 2009.

Authors:  S Atkin; S Anaraki; P Gothard; A Walsh; D Brown; R Gopal; J Hand; D Morgan
Journal:  Euro Surveill       Date:  2009-03-12

2.  Structure of the Lassa virus nucleoprotein reveals a dsRNA-specific 3' to 5' exonuclease activity essential for immune suppression.

Authors:  Kathryn M Hastie; Christopher R Kimberlin; Michelle A Zandonatti; Ian J MacRae; Erica Ollmann Saphire
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-24       Impact factor: 11.205

3.  Thoracic radiography as a refinement methodology for the study of H1N1 influenza in cynomologus macaques (Macaca fascicularis).

Authors:  Douglas L Brining; John S Mattoon; Lisa Kercher; Rachael A LaCasse; David Safronetz; Heinz Feldmann; Michael J Parnell
Journal:  Comp Med       Date:  2010-10       Impact factor: 0.982

4.  Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.

Authors:  Xiaohong Jiang; Tim J Dalebout; Peter J Bredenbeek; Ricardo Carrion; Kathleen Brasky; Jean Patterson; Marco Goicochea; Joseph Bryant; Maria S Salvato; Igor S Lukashevich
Journal:  Vaccine       Date:  2010-12-08       Impact factor: 3.641

5.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

6.  Detection of Lassa virus, Mali.

Authors:  David Safronetz; Job E Lopez; Nafomon Sogoba; Sékou F Traore'; Sandra J Raffel; Elizabeth R Fischer; Hideki Ebihara; Luis Branco; Robert F Garry; Tom G Schwan; Heinz Feldmann
Journal:  Emerg Infect Dis       Date:  2010-07       Impact factor: 6.883

7.  Cap binding and immune evasion revealed by Lassa nucleoprotein structure.

Authors:  Xiaoxuan Qi; Shuiyun Lan; Wenjian Wang; Lisa McLay Schelde; Haohao Dong; Gregor D Wallat; Hinh Ly; Yuying Liang; Changjiang Dong
Journal:  Nature       Date:  2010-11-17       Impact factor: 49.962

8.  Pathogenesis of Lassa fever in cynomolgus macaques.

Authors:  Lisa E Hensley; Mark A Smith; Joan B Geisbert; Elizabeth A Fritz; Kathleen M Daddario-DiCaprio; Tom Larsen; Thomas W Geisbert
Journal:  Virol J       Date:  2011-05-06       Impact factor: 4.099

9.  Evaluation of Lassa antiviral compound ST-193 in a guinea pig model.

Authors:  Kathleen A Cashman; Mark A Smith; Nancy A Twenhafel; Ryan A Larson; Kevin F Jones; Robert D Allen; Dongcheng Dai; Jarasvech Chinsangaram; Tove' C Bolken; Dennis E Hruby; Sean M Amberg; Lisa E Hensley; Mary C Guttieri
Journal:  Antiviral Res       Date:  2011-03-01       Impact factor: 5.970

Review 10.  Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever.

Authors:  Daniel G Bausch; Christiane M Hadi; Sheik Humarr Khan; Juan J L Lertora
Journal:  Clin Infect Dis       Date:  2010-11-08       Impact factor: 9.079

View more
  24 in total

1.  Delayed inflammatory and cell death responses are associated with reduced pathogenicity in Lujo virus-infected cynomolgus macaques.

Authors:  Angela L Rasmussen; Nicolas Tchitchek; David Safronetz; Victoria S Carter; Christopher M Williams; Elaine Haddock; Marcus J Korth; Heinz Feldmann; Michael G Katze
Journal:  J Virol       Date:  2014-12-17       Impact factor: 5.103

2.  Evaluating the Biological Role of Lassa Viral Z Protein-Mediated RIG-I Inhibition Using a Replication-Competent Trisegmented Pichinde Virus System in an Inducible RIG-IN Expression Cell Line.

Authors:  Da Di; Qinfeng Huang; Hinh Ly; Yuying Liang
Journal:  J Virol       Date:  2022-08-01       Impact factor: 6.549

3.  Ribavirin for treating Lassa fever: A systematic review of pre-clinical studies and implications for human dosing.

Authors:  Alex P Salam; Alexandre Duvignaud; Marie Jaspard; Denis Malvy; Miles Carroll; Joel Tarning; Piero L Olliaro; Peter W Horby
Journal:  PLoS Negl Trop Dis       Date:  2022-03-30

4.  Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.

Authors:  Andrea Marzi; Friederike Feldmann; Thomas W Geisbert; Heinz Feldmann; David Safronetz
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

5.  A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.

Authors:  David Safronetz; Chad Mire; Kyle Rosenke; Friederike Feldmann; Elaine Haddock; Thomas Geisbert; Heinz Feldmann
Journal:  PLoS Negl Trop Dis       Date:  2015-04-17

Review 6.  Human hemorrhagic Fever causing arenaviruses: molecular mechanisms contributing to virus virulence and disease pathogenesis.

Authors:  Junjie Shao; Yuying Liang; Hinh Ly
Journal:  Pathogens       Date:  2015-05-21

Review 7.  Animal Models for the Study of Rodent-Borne Hemorrhagic Fever Viruses: Arenaviruses and Hantaviruses.

Authors:  Joseph W Golden; Christopher D Hammerbeck; Eric M Mucker; Rebecca L Brocato
Journal:  Biomed Res Int       Date:  2015-07-21       Impact factor: 3.411

8.  Geographic distribution and genetic characterization of Lassa virus in sub-Saharan Mali.

Authors:  David Safronetz; Nafomon Sogoba; Job E Lopez; Ousmane Maiga; Eric Dahlstrom; Marko Zivcec; Friederike Feldmann; Elaine Haddock; Robert J Fischer; Jennifer M Anderson; Vincent J Munster; Luis Branco; Robert Garry; Stephen F Porcella; Tom G Schwan; Heinz Feldmann
Journal:  PLoS Negl Trop Dis       Date:  2013-12-05

9.  Lassa Virus Seroprevalence in Sibirilia Commune, Bougouni District, Southern Mali.

Authors:  Nafomon Sogoba; Kyle Rosenke; Jennifer Adjemian; Sory Ibrahim Diawara; Ousmane Maiga; Moussa Keita; Drissa Konaté; Abdoul Salam Keita; Ibrahim Sissoko; Matt Boisen; Diana Nelson; Darin Oottamasathien; Molly Millett; Robert F Garry; Luis M Branco; Sékou F Traoré; Seydou Doumbia; Heinz Feldmann; David Safronetz
Journal:  Emerg Infect Dis       Date:  2016-04       Impact factor: 6.883

10.  The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset.

Authors:  David Safronetz; Kyle Rosenke; Jonna B Westover; Cynthia Martellaro; Atsushi Okumura; Yousuke Furuta; Joan Geisbert; Greg Saturday; Takashi Komeno; Thomas W Geisbert; Heinz Feldmann; Brian B Gowen
Journal:  Sci Rep       Date:  2015-10-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.